EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical use of multipotent mesenchymal stem cells in children after allogeneic bone marrow transplantation: the experience of the N.N. Blokhin National Medical Research Center of Oncology

R. R. Fatkhullin, M. V. Kiselevsky, E. B. Machneva, K. I. Kirgizov, I. O. Kostareva, D. S. Smirnova, T. Z. Aliev, M. A. Shervashidze, N. A. Batmanova, T. T. Valiev, T. V. Gorbunova, Nara G. Stepanyan und 1 weitere

Pediatric Hematology/Oncology and Immunopathology · 30.06.2026 · 25 (2) · 138-144

DOI: 10.24287/j.1126 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Hematology/Oncology and Immunopathology, online erschienen am 30.06.2026. Verfasst von R. R. Fatkhullin und 12 weiteren Autor:innen. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is one of the most important curative and consolidating treatment options for hematologic malignancies, immunologic diseases, and solid tumors. Nevertheless, its use may be limited due to life-threatening post-transplant complications, such as acute graft-versus-host disease (aGVHD), chronic graft-versus-host disease (cGVHD), and poor graft function. The standard treatment for these complications includes the administration of immunosuppressive drugs. However, their side effects and limited effectiveness necessitate the continued search for additional treatments, among which the use of mesenchymal stem cells (MSCs) may prove highly effective. Materials and methods. In this retrospective/prospective study conducted from 2021 to 2025, we enrolled 25 patients aged from 10 months to 16 years (with a median age of 11 years) with refractory aGVHD, cGVHD, and/or poor graft function after allo-HSCT. MSCs isolated from the bone marrow of allogeneic donors and cultured to passages 2–3 were administered intraosseously/intravenously or through a nasojejunal tube every 1–2 weeks. The primary endpoint was clinical response to therapy.

Results

The median cell product dose was 20 (4–69) × 106 cells/kg recipient body weight. A response to MSC therapy was achieved in 15 (60.0%) out of 25 patients: in 8/9 (88.9%) patients with isolated poor graft function, in 4/6 patients who had both poor graft function and GVHD, and in 3/10 patients with isolated aGVHD/cGVHD. No adverse events associated with MSC administration were observed in any patient.

Conclusion

The use of allogeneic MSCs in pediatric patients with refractory complications of allo-HSCT is a safe and potentially effective method. Our results are consistent with published data and warrant prospective randomized studies with a structured design and more precise response criteria.

Zitieren

APA

Fatkhullin, R. R., Kiselevsky, M. V., Machneva, E. B., Kirgizov, K. I., Kostareva, I. O., Smirnova, D. S., Aliev, T. Z., Shervashidze, M. A., Batmanova, N. A., Valiev, T. T., Gorbunova, T. V., Stepanyan, N. G., & Varfolomeeva, S. R. (2026). Clinical use of multipotent mesenchymal stem cells in children after allogeneic bone marrow transplantation: the experience of the N.N. Blokhin National Medical Research Center of Oncology. Pediatric Hematology/Oncology and Immunopathology, 25(2), 138-144. https://doi.org/10.24287/j.1126

Vancouver

Fatkhullin RR, Kiselevsky MV, Machneva EB, Kirgizov KI, Kostareva IO, Smirnova DS, et al. Clinical use of multipotent mesenchymal stem cells in children after allogeneic bone marrow transplantation: the experience of the N.N. Blokhin National Medical Research Center of Oncology. Pediatric Hematology/Oncology and Immunopathology. 2026;25(2):138-144. doi:10.24287/j.1126

BibTeX
@article{Fatkhullin2026,
  author = {Fatkhullin, R. R. and Kiselevsky, M. V. and Machneva, E. B. and Kirgizov, K. I. and Kostareva, I. O. and Smirnova, D. S. and Aliev, T. Z. and Shervashidze, M. A. and Batmanova, N. A. and Valiev, T. T. and Gorbunova, T. V. and Stepanyan, Nara G. and Varfolomeeva, S. R.},
  title = {Clinical use of multipotent mesenchymal stem cells in children after allogeneic bone marrow transplantation: the experience of the N.N. Blokhin National Medical Research Center of Oncology},
  journal = {Pediatric Hematology/Oncology and Immunopathology},
  year = {2026},
  volume = {25},
  number = {2},
  pages = {138--144},
  doi = {10.24287/j.1126}
}
Kostenlos starten →